Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708

Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK (2020) Prostate cancer incidence and survival, by stage and race/ethnicity—United States, 2001–2017. MMWR Morb Mortal Wkly Rep 69:1473–1480. https://doi.org/10.15585/mmwr.mm6941a1

Clark R, Herrera-Caceres J, Kenk M, Fleshner N (2022) Clinical management of prostate cancer in high-risk genetic mutation carriers. Cancers 14:1004. https://doi.org/10.3390/cancers14041004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crawford ED (1994) Changing concepts in the management of advanced prostate cancer. Urology 44:67–74. https://doi.org/10.1016/S0090-4295(94)80247-5

Article  Google Scholar 

Steele CB, Li J, Huang B, Weir HK (2017) Prostate cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer 123:5160–5177. https://doi.org/10.1002/cncr.31026

Article  PubMed  Google Scholar 

Ritch C, Cookson M (2018) Recent trends in the management of advanced prostate cancer. F1000Res 7:1513. https://doi.org/10.12688/f1000research.15382.1

Article  CAS  Google Scholar 

Zheng Y, Ye Y, Chen L, Ma Z, Liu L, Cheng G et al (2022) Prevalence and outcomes of focal ablation versus prostatectomy for elderly patients with prostate cancer: a population-based study. J Natl Cancer Cent 2(1):25–32. https://doi.org/10.1016/j.jncc2021.11.005

Article  PubMed  Google Scholar 

Cam Pham P, Van Pham T, Doan Dinh L, Thuan Nguyen L, Viet Le N, Bich Bui M et al (2024) BRCA mutation in Vietnamese prostate cancer patients: a mixed cross-sectional study and case series. Oncologie 26:247–256. https://doi.org/10.1515/oncologie-2023-0556

Article  Google Scholar 

LUO C, ZHANG J, AN Y, LIU X, LI S et al (2024) MAPK9 as a therapeutic target: unveiling ferroptosis in localized prostate cancer progression. BIOCELL 48:771–792. https://doi.org/10.32604/biocell.2024.048878

Article  Google Scholar 

U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs [Internet]. FDA; (2024) [cited 2024 Apr 2]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process

Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S et al (2022) The efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: a network meta-analysis of randomized trials. Eur Urol Oncol 5:138–145. https://doi.org/10.1016/j.euo.2021.07.002

Article  PubMed  Google Scholar 

Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R et al (2020) Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 382:2187–2196. https://doi.org/10.1056/NEJMoa2004325

Article  CAS  PubMed  Google Scholar 

Kawahara N, Kawaguchi R, Yamamoto K, Nishikawa K, Matsuoka M, Maehana T et al (2024) The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for non-adverse Relugolix Administration (NARA) trial. Trials 25:68. https://doi.org/10.1186/s13063-024-07923-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

De La Cerda J, Dunshee C, Gervasi L, Sieber P, Belkoff L, Tutrone R et al (2023) A phase I clinical trial evaluating the safety and dosing of relugolix with novel hormonal therapy for the treatment of advanced prostate cancer. Target Oncol 18:383–390. https://doi.org/10.1007/s11523-023-00967-5

Article  PubMed  Google Scholar 

Shu Y, Ding Y, Liu Y, Wu P, He X, Zhang Q (2022) Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol 13:862508. https://doi.org/10.3389/fphar.2022.862508

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Dong C, He X, Shu Y, Wu P, Zou J (2022) Post-marketing safety of Vemurafenib: a real-world pharmacovigilance study of the FDA adverse event reporting system. J Pharm Pharm Sci 25:377–390. https://doi.org/10.18433/jpps33020

Article  PubMed  Google Scholar 

He W, Wang Y, Chen K (2024) A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam. Front Pharmacol 15:1278442. https://doi.org/10.3389/fphar.2024.1278442

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shu Y, He X, Liu Y, Wu P, Zhang Q (2022) A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system. Clin Epidemiol 14:789–802. https://doi.org/10.2147/CLEP.S365513

Article  PubMed  PubMed Central  Google Scholar 

Shu Y, Ding Y, Dai B, Zhang Q (2022) A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf 21:563–572. https://doi.org/10.1080/14740338.2022.2016696

Article  PubMed  Google Scholar 

U.S. Food and Drug Administration. ORGOVYX (relugolix) prescribing information [Internet]. FDA; (2020) [cited 2024 Apr 2]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf

European Medicines Agency. ORGOVYX (relugolix) summary of product characteristics [Internet]. EMA (2022) [cited 2024 Apr 2]. https://www.ema.europa.eu/en/documents/product-information/orgovyx-epar-product-information_en.pdf

Saraswat L, Bhattacharya S (2022) Relugolix combination therapy for endometriosis pain. Lancet 399:2244–2245. https://doi.org/10.1016/S0140-6736(22)00663-8

Article  CAS  PubMed  Google Scholar 

Venturella R, Rechberger T, Zatik J, Wagman RB, Zhu E, Rakov VG et al (2023) Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials. Gynecol Endocrinol 39:2249107. https://doi.org/10.1080/09513590.2023.2249107

Article  CAS  PubMed  Google Scholar 

Spratt DE, George DJ, Shore ND, Cookson MS, Saltzstein DR, Tutrone R et al (2024) Efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.7279

Article  PubMed  PubMed Central  Google Scholar 

Sahu KK, Tripathi N, Agarwal N, Swami U (2022) Relugolix in the management of prostate cancer. Expert Rev Anticancer Ther 22:891–902. https://doi.org/10.1080/14737140.2022.2105209

Article  CAS  PubMed  Google Scholar 

Saad F, Shore ND (2021) Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Ther Adv Med Oncol 13:1–12. https://doi.org/10.1177/1758835921998586

Article  CAS  Google Scholar 

Sountoulides P, Rountos T (2013) Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol 2013:240108. https://doi.org/10.1155/2013/240108

Article  CAS  PubMed  PubMed Central  Google Scholar